<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="294">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171247</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00004492</org_study_id>
    <nct_id>NCT02171247</nct_id>
  </id_info>
  <brief_title>Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)</brief_title>
  <official_title>Comparison of the Use of High Iodine Concentration Contrast Material (Isovue 370) vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Computed Tomography Angiogram (CTA) scans are performed routinely to look at the vessels in
      the body as an alternative to directly injecting contrast into the vessels and taking
      pictures. Different types of intravenous (into the vein, IV) contrast are available to fill
      the vessels and make them easier to see. The purpose of the study is to determine the best
      type of contrast for this scan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Contrast to Noise Ratio</measure>
    <time_frame>during scan, approximately 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Contrast-to-noise ratios (CNRs) were calculated as follows: CNR = (vascular attenuation âˆ’ myocardium attenuation) / SD of mean noise attenuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Image Quality</measure>
    <time_frame>during scan, approximately 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depiction of Branch Vessels - coronary branch depiction was performed as consensus decisions of two blinded radiologists. Criteria used was abscence or presence of vessels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Motion Artifact</measure>
    <time_frame>during scan, approximately 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The outcome will be measured by individual scores. The scores from multiple readers will be averaged.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Attenuation of the Ascending Aorta and Coronary Arteries</measure>
    <time_frame>during scan, approximately 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The investigator will measure the length of visualized coronary artery for the left anterior descending, left circumflex and right coronary arteries as a way of quantifying visualization of distal coronary segments.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Coronary Computed Tomographic Angiography</condition>
  <arm_group>
    <arm_group_label>Isovue 370</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isovue 370 is a contrast agent with increased iodine concentration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Visipaque 320</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard protocol is Visipaque 320.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovue 370</intervention_name>
    <description>Isovue 370 is a contrast agent with increased iodine concentration.</description>
    <arm_group_label>Isovue 370</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visipaque 320</intervention_name>
    <description>Visipaque 320 is standard protocol.</description>
    <arm_group_label>Visipaque 320</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients who are referred for coronary CTA for suspected or known coronary
             artery disease

        Exclusion Criteria:

          -  creatinine greater than 2.0

          -  allergy to contrast media

          -  patients under the age of 18

          -  women who are pregnant or breast feeding

          -  patients with cardiac arrhythmia will also be excluded
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Boll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 28, 2014</lastchanged_date>
  <firstreceived_date>June 12, 2014</firstreceived_date>
  <firstreceived_results_date>July 28, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary computed tomographic angiography</keyword>
  <keyword>contrast</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contrast Media</mesh_term>
    <mesh_term>Iodixanol</mesh_term>
    <mesh_term>Iopamidol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>35 subjects signed consent. 2 subjects were not assigned to a arm and were withdrawn from study due to impaired renal function. 33 subjects completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Visipaque 320</title>
          <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
        </group>
        <group group_id="P2">
          <title>Isovue 370</title>
          <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Visipaque 320</title>
          <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
        </group>
        <group group_id="B2">
          <title>Isovue 370</title>
          <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18 years and older</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Contrast to Noise Ratio</title>
        <description>Contrast-to-noise ratios (CNRs) were calculated as follows: CNR = (vascular attenuation âˆ’ myocardium attenuation) / SD of mean noise attenuation.</description>
        <time_frame>during scan, approximately 3 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Visipaque 320</title>
            <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370</title>
            <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Contrast to Noise Ratio</title>
            <description>Contrast-to-noise ratios (CNRs) were calculated as follows: CNR = (vascular attenuation âˆ’ myocardium attenuation) / SD of mean noise attenuation.</description>
            <units>CNR</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18.6" spread="5.2"/>
                  <measurement group_id="O2" value="20.5" spread="4.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Image Quality</title>
        <description>Depiction of Branch Vessels - coronary branch depiction was performed as consensus decisions of two blinded radiologists. Criteria used was abscence or presence of vessels.</description>
        <time_frame>during scan, approximately 3 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Visipaque 320</title>
            <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370</title>
            <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Image Quality</title>
            <description>Depiction of Branch Vessels - coronary branch depiction was performed as consensus decisions of two blinded radiologists. Criteria used was abscence or presence of vessels.</description>
            <units>% of coronary branches visualized</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Conus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.8"/>
                  <measurement group_id="O2" value="94.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sinoatrial Nodal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.5"/>
                  <measurement group_id="O2" value="82.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diagonal1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="87.5"/>
                  <measurement group_id="O2" value="35.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diagonal1 and Diagonal2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.5"/>
                  <measurement group_id="O2" value="64.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Obutse Marginal1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.8"/>
                  <measurement group_id="O2" value="29.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Obutse Marginal1 and Obutse Marginal2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.3"/>
                  <measurement group_id="O2" value="70.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Acute marginal1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62.5"/>
                  <measurement group_id="O2" value="47.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Acute marginal1 and Acute marginal2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.8"/>
                  <measurement group_id="O2" value="52.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Septal perforator</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.8"/>
                  <measurement group_id="O2" value="88.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Posterolateral</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.3"/>
                  <measurement group_id="O2" value="64.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Motion Artifact</title>
        <description>The outcome will be measured by individual scores. The scores from multiple readers will be averaged.</description>
        <time_frame>during scan, approximately 3 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Data was not collected and therefore not analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Visipaque 320</title>
            <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370</title>
            <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Motion Artifact</title>
            <description>The outcome will be measured by individual scores. The scores from multiple readers will be averaged.</description>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Attenuation of the Ascending Aorta and Coronary Arteries</title>
        <description>The investigator will measure the length of visualized coronary artery for the left anterior descending, left circumflex and right coronary arteries as a way of quantifying visualization of distal coronary segments.</description>
        <time_frame>during scan, approximately 3 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Visipaque 320</title>
            <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
          </group>
          <group group_id="O2">
            <title>Isovue 370</title>
            <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Attenuation of the Ascending Aorta and Coronary Arteries</title>
            <description>The investigator will measure the length of visualized coronary artery for the left anterior descending, left circumflex and right coronary arteries as a way of quantifying visualization of distal coronary segments.</description>
            <units>CNR</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>ascending aorta</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.5" spread="4.8"/>
                  <measurement group_id="O2" value="21.6" spread="4.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>coronary arteries</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.4" spread="5.3"/>
                  <measurement group_id="O2" value="20.3" spread="4.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Visipaque 320</title>
          <description>Standard protocol is Visipaque 320.
Visipaque 320: Visipaque 320 is standard protocol.</description>
        </group>
        <group group_id="E2">
          <title>Isovue 370</title>
          <description>Isovue 370 is a contrast agent with increased iodine concentration.
Isovue 370: Isovue 370 is a contrast agent with increased iodine concentration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel T Boll, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-2711</phone>
      <email>daniel.boll@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
